CVS Health Corporation (CVS). Below are some highlights from the above linked analysis:
Company Description: CVS Health Corporation is the largest pharmacy health care provider in the U.S.
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
CVS is trading at a discount to only 1.) above. Since CVS's tangible book value is not meaningful, a Graham number can not be calculated. When also considering the NPV MMA Differential, the stock is trading at a 45.3% discount to its calculated fair value of $169.51. CVS earned a Star in this section since it is trading at a fair value.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
CVS earned one Star in this section for 3.) above. CVS earned a Star for having an acceptable score in at least two of the four Key Metrics measured. Rolling 4-yr Div. > 15% means that dividends grew on average in excess of 15% for each consecutive 4 year period over the last 10 years (2006-2009, 2007-2010, 2008-2011, etc.) I consider this a key metric since dividends will double every 5 years if they grow by 15%. The company has paid a cash dividend to shareholders every year since 1916 and has increased its dividend payments for 13 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
CVS earned a Star in this section for its NPV MMA Diff. of the $13,186. This amount is in excess of the $2,200 target I look for in a stock that has increased dividends as long as CVS has. The stock's current yield of 1.83% exceeds the 1.81% estimated 20-year average MMA rate.
Peers: The company's peer group includes: Express Scripts Holding Company (ESRX) with a 0.0% yield, Rite Aid Corporation (RAD) with a 0.0% yield, and Walgreen Co. (WBA) with a 1.9% yield.
Conclusion: CVS earned one Star in the Fair Value section, earned one Star in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of three Stars. This quantitatively ranks CVS as a 3-Star Hold stock.
Using my D4L-PreScreen.xls model, I determined the share price would need to increase to $197.89 before CVS's NPV MMA Differential decreased to the $2,200 minimum that I look for in a stock with 13 years of consecutive dividend increases. At that price the stock would yield 0.9%.
Resetting the D4L-PreScreen.xls model and solving for the dividend growth rate needed to generate the target $2,200 NPV MMA Differential, the calculated rate is 13.4%. This dividend growth rate is below the 20.0% used in this analysis, thus providing a margin of safety. CVS has a risk rating of 2.25 which classifies it as a Medium risk stock.
With a free cash flow payout of 30% (down from 31%) and a debt to total capital of 50% (up from 42%), the company's dividend metrics are very strong and it should have no problem raising its dividends in the coming years. The stock is trading below my $169.51 calculated fair value and has demonstrated an exceptional ability to grow its dividend at a high rate, averaging nearly 25% per year since 2005. However, its current yield is well below my minimum for my Dividend Growth Portfolio, but will give it consideration for my High Dividend Growth Portfolio.
Disclaimer: Material presented here is for informational purposes only. The above quantitative stock analysis, including the Star rating, is mechanically calculated and is based on historical information. The analysis assumes the stock will perform in the future as it has in the past. This is generally never true. Before buying or selling any stock you should do your own research and reach your own conclusion. See my Disclaimer for more information.
Full Disclosure: At the time of this writing, I held no position in CVS (0.0% of my Dividend Growth Portfolio). See a list of all my Dividend Growth Portfolio holdings here.
- Duke Energy (DUK) Dividend Stock Analysis
- Emerson Electric Co. (EMR) Dividend Stock Analysis
- Kimberly-Clark Co. (KMB) Dividend Stock Analysis
- Illinois Tool Works Inc. (ITW) Dividend Stock Analysis
- Wells Fargo & Company (WFC) Dividend Stock Analysis
- More Stock Analysis
Tags: CVS, ESRX, RAD, WBA,
Popular Posts - Last 7 days
Over the last 12-18 months, there have been several prognosticators saying dividend stocks are extremely over valued. In many cases, I woul...
It is a well-documented fact that a significant portion of the historical equity returns are a result of reinvested dividends. In Triumph of...
There are only few things in life that I consider myself an expert in , but when it comes to making investing mistakes I have earned several...
Linked here is a detailed quantitative analysis of International Business Machines Corp. (IBM). Below are some highlights from the above li...
Linked here is a detailed quantitative analysis of Duke Energy (DUK). Below are some highlights from the above linked analysis: Company D...
Each weekend I highlight any notable articles that I came across over the past week. Though I may not always agree with each of the articles...
As mentioned in previous articles, I love inspirational (and other) quotes . I see quotes as a portal to someone’s inner self. They reveal m...
In an utopian world, the perfect dividend stock would be one that is both high-yield and provide a high dividend growth rate. Its share pri...
Linked here is a detailed quantitative analysis of The Clorox Company (CLX). Below are some highlights from the above linked analysis: Co...
Presented below are are my Dividend Growth Stocks portfolio holdings. This is not a recommendation to buy these securities. I have classifi...